Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16820012 | 1.00 | CHRNA7 (0.37) | CHRNA7SOS1SLC6A4SLC6A3RORC | |
| SCHEMBL16845482 | 0.89 | CA1 (0.42) | CHRNA7SOS1CA1CA2ACHE | |
| SCHEMBL15556891 | 0.89 | CA1 (0.42) | CHRNA7SOS1CA1CA2ACHE | |
| SCHEMBL16845535 | 0.89 | CHRNA7 (0.38) | CHRNA7SOS1CA1CA2ACHE | |
| SCHEMBL20707901 | 0.86 | — | — | |
| SCHEMBL16819954 | 0.83 | SOS1 (0.41) | CHRNA7SOS1CA1CA2ALDH1A1 | |
| SCHEMBL16819992 | 0.83 | SOS1 (0.41) | CHRNA7SOS1CA1CA2ALDH1A1 | |
| SCHEMBL16845431 | 0.83 | CA2 (0.38) | CHRNA7SOS1SLC6A4SLC6A3CA1 | |
| SCHEMBL16819897 | 0.83 | CA2 (0.38) | CHRNA7SOS1SLC6A4SLC6A3CA1 | |
| SCHEMBL16819946 | 0.83 | SOS1 (0.41) | CHRNA7SOS1CA1CA2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2888229-B1 | alpha7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF | MERCK SHARP & DOHME (US) | 2019-02-06 | — | — | EP | disclosed |
| US-9790173-B2 | Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I | MERCK SHARP & DOHME CORP. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | MERCK SHARP & DOHME CORP. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | MERCK SHARP & DOHME CORP. | 2015-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158628-A1 | ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I | CHRNA7, CHRNA5, CHRNA6 | CHRNA7 1/4885SOS1 4309/4885SLC6A4 1022/4885 |
| US-20150175534-A1 | Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I | CHRNA7, CHRNA6, CHRNA5 | CHRNA7 1/4885SOS1 4266/4885SLC6A4 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.